Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.911 USD | -0.97% | -5.07% | -34.56% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.56% | 139M | |
+9.70% | 115B | |
+12.05% | 106B | |
-2.59% | 21.96B | |
-12.37% | 21.87B | |
-5.29% | 19.21B | |
-3.55% | 18.08B | |
-38.57% | 17.71B | |
+7.14% | 14.32B | |
+35.57% | 12.42B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Piper Sandler Adjusts Price Target on Seres Therapeutics to $9 From $7, Reiterates Overweight Rating